Dynamic and delayed contrast enhancement in upper abdominal MRI studies: comparison of gadoxetic acid and gadobutrol.
OBJECTIVE
To prospectively compare contrast properties of extracelullar (gadobutrol) and hepatospecific (gadoxetic acid) contrast agents in upper abdominal MRI studies.


METHODS
Standardized (0.1 ml/kg) dose of gadobutrol (56 subjects) and gadoxetic acid (51 subjects) was administered intravenously by MRI-compatible injector at 2 ml/s, followed by 20 ml saline flush. MR signal intensity changes (SIC) between precontrast scans and arterial phase, portal venous phase, equilibrium, and delayed scans at 10 and 20 min were measured in abdominal aorta, portal vein, common bile duct, liver, and spleen. Mean SIC values for gadobutrol and gadoxetic acid were compared by a two-sample t-test with p-value <0.05 considered significant.


RESULTS
In abdominal aorta, the mean SIC in the arterial phase did not significantly differ between gadobutrol (330%) and gadoxetic acid (295%). In portal vein, the mean SIC in the portal venous phase significantly differed between gadobutrol (267%) and gadoxetic acid (176%). Liver parenchyma enhancement was significantly higher for gadobutrol than for gadoxetic acid in both arterial phase (28 versus 13%) and portal venous phase (81 versus 46%). On the contrary, gadobutrol reached significantly lower mean SIC in the liver on delayed scans at 10 min (47 versus 59%) and 20 min (40 versus 67%), as well as in common bile duct at 10 min (54 versus 133%) and 20 min (57 versus 457%), respectively. In the spleen, mean SIC for gadobutrol was significantly higher at all phases.


CONCLUSIONS
Gadobutrol showed superior enhancement of upper abdominal structures in the dynamic phases whereas gadoxetic acid showed better enhancement of the hepatobiliary structures on delayed scans.
Zizka
Jan
J
Department of Radiology, Charles University Hospital, Sokolská 581, CZ-500 05 Hradec Králové, Czech Republic. zizka@fnhk.cz
Klzo
Ludovít
L
Ferda
Jirí
J
Mrklovský
Milan
M
Bukac
Josef
J
D000005:Abdomen / Q000473:pathology*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001012:Aorta, Abdominal / Q000187:drug effects; D003135:Common Bile Duct / Q000187:drug effects; D003287:Contrast Media; D005260:Female; D019786:Gadolinium DTPA; D006801:Humans; D007089:Image Enhancement; D007090:Image Interpretation, Computer-Assisted; D007275:Injections, Intravenous; D008099:Liver / Q000187:drug effects; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds; D011169:Portal Vein / Q000187:drug effects; D011446:Prospective Studies; D012107:Research Design; D012815:Signal Processing, Computer-Assisted; D013154:Spleen / Q000187:drug effects
D003287:Contrast Media; D009942:Organometallic Compounds; C073590:gadolinium ethoxybenzyl DTPA; C090600:gadobutrol; D019786:Gadolinium DTPA